Simply Younger

Some of you are aware that I have been fighting a long battle back to health. What I originally thought was an allergy to gluten back in 2012 ended up being a form of lymphoma. Accurate diagnosis didn’t happen till November 2018. My stubborn self and dislike of anything hospital was partially at play but also cutaneous t-cell lymphoma is one that goes misdiagnosed for some time with most. I was lucky enough to be informed by someone I was giving a ride to who had been diagnosed with the same thing and in treatment for many years before we met.
To add lucky duck icing on top of that good news I was fortunate enough to have a friend of the family that is an oncologist who’s specialty is lymphoma and leukemia. What luck to say the least.
Now here is the interesting twist. I had been through diet, supplementation and Dr. Google been addressing what I thought was something systemic but by no means did I really think that I had cancer. I had my primary Dr. do all of my blood tests to make sure that everything internal that I couldn’t see was functioning properly and continued on my path to recovery. I still am not sure I agree with the diagnosis but I have accepted it and respect it, however I reserve my right to remain a skeptic. Have I made all of the right decisions for treatment along the way? I don’t know. We will see.
Back to the diagnosis and oncologist. Though he recommended that I have further tests done, I chose not to. Many of the neoplasia(tumors) had already resolved or reduced in size significantly. In other words my immune system was doing its job and my skin was fixing itself and expressing all of the diseased tissues gradually over time. REEEEEALLY GROSS. On the other hand, no nasty scarring. Just a prolonged recovery and a lot of self care.
Cutaneous T-Cell Lymphoma which was originally called Mycosis fungoides was first described in 1806 by French dermatologist Jean-Louis-Marc Alibert. The name mycosis fungoides is very misleading—it loosely means “mushroom-like fungal disease”. The disease, however, is not a fungal infection but rather a type of non-Hodgkin’s lymphoma. It was so named because Alibert described the skin tumors of a severe case as having a mushroom-like appearance. Which is exactly why I had no clue that it was cancer. I frankly thought I was just a sick ass dirty bird that drank way too much and ended up with a really bad fungal infection that was paying the piper.
All this to say…I identify with Legion…LoL. I swear this guy had the same thing as me. Him and Job. Too much fun.
Now if I could just figure out how to write a book. How to publish. Because I have an amazing story to tell about my recovery from a disease I didn’t know I had. And how my recovery and principles learned in A.A. helped my mentally remain strong through my return to health.
I also want to help people. I want to help people not have to go through what I did. And here is why…
When all this started back in September of 2017 I made some drastic lifestyle changes and dedicated myself to learning how to optimize health and existence. Along the way I have explored many different diet trends and tried many a different thing eventually arriving where I am at today almost fully recovered.
I still have a little ways to go, but I expect that the full recovery process will take about 42 months or 3.5 years. I’ve been documenting some of it at https://3.5tolife.com
And the best part is my body looks and feels significantly younger and I don’t think it is anything magic that I have done. Just followed some basic ideas and rules.
What if cancer, dementia, diabetes and cardio vascular issues were all simply the process of aging taking its course? I imagine that would mean that all we have to do is figure out what it means to be simply younger and go there.
That is my starting point…Simply Younger

Unusual variants of mycosis fungoides – NIH

~Content Source

Conventional presentations of mycosis fungoides may be diagnostically challenging, particularly in light of the controversial boundaries defining the disease. Variant presentations of this cutaneous T-cell lymphoma add a further layer of complexity, requiring a sophisticated and informed perspective when evaluating lymphoid infiltrates in the skin. Herein we discuss well-defined (WHO-EORTC) variants pagetoid reticulosis, granulomatous slack skin and folliculotropic mycosis fungoides as well as less well-defined morphologic/architectural variants, and divergent immunohistochemical presentations of this typically indolent T-cell lymphoproliferative disease.

Narrowband-UVB in Early Stage Cutaneous T-Cell Lymphoma

ISRN Dermatology
Volume 2014, Article ID 951821, 4 pages
http://dx.doi.org/10.1155/2014/951821

Efficacy and Side Effects of Narrowband-UVB in Early Stage Cutaneous T-Cell Lymphoma in Jordanian Patients

Salah A. AbdallatAyman S. AlqaqaaNidal A. Obaidat, and Rameh F. Alnueimi

Department of Dermatology, King Hussein Medical Center, Amman 11941, Jordan

Received 1 November 2013; Accepted 31 December 2013; Published 19 February 2014

Academic Editors: B. Amichai, F. M. Camacho, L. Dourmishev, A. Oakley, and W. Vanscheidt

Copyright © 2014 Salah A. Abdallat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Many studies, on light-skinned patients, suggested narrowband-UVB to be effective and safe for the treatment of early stage cutaneous T-cell lymphoma. Objectives. To evaluate the efficacy and side effects of narrowband-UVB in treatment of early stage cutaneous T-cell lymphoma in patients with skin phototypes III, IV, and V. Methods. A total of 27 patients with the diagnosis of early stage cutaneous T-cell lymphoma were involved in this prospective study. All patients received narrowband-UVB as monotherapy until clearance or a maximum of 42 sessions. Patients with complete clearance were followed for six months or relapse. Rate of clearance, number of sessions, and cumulative narrowband-UVB dose needed to achieve clearance, percentage of patients remaining in remission at 6 months, and side effects were analyzed. Results. Within 5–14 weeks (15–42 sessions), using cumulative narrowband-UVB dose ranging from 17.3 to 48.2 J/cm2, complete remission was achieved in 76.4% of patients. The rest of the patients achieved partial remission. Six months after discontinuation of the treatment, 42.8% of patients with complete remission remained in remission. Transient erythema in 11.1% of patients and mild hyperpigmentation in 14.8% of patients were the only side effects encountered during this study. Conclusion. We conclude that narrowband-UVB phototherapy is safe and effective for the treatment of early stage cutaneous T-cell lymphoma in darker-skinned patients.

1. Introduction

Cutaneous T-cell lymphoma (CTCL) is a group of lymphoproliferative disorders with clonal expansion of T helper cells, or rarely T suppressor/killer cells or NK cells, with localization to the skin. This group is characterized by an increased CD4+ cells: CD4/CD8 > 10, and/or an expansion of T cells with a loss of 1 or more of the normal T-cell antigens (CD2, CD3, and CD5) [1].

Cutaneous T-cell lymphomas are very rare, with a prevalence of 5/1000000 per year [12]. They are classified into a group with indolent clinical behavior, which includes mycosis fungoides (MF) and its variants (62%), and primary cutaneous CD30+ lymphoproliferative disorders (26%) and a group with aggressive clinical behavior (12%) like Sézary syndrome and adult T-cell leukemia/lymphoma [2].

MF, the commonest form of CTCL, presents as patches and plaques over trunk and proximal extremities, without internal involvement. It has a predilection for older adults and male gender [35]. MF is classified into early (stage IA, IB, and IIA) and advanced (stage IIB, III and IV) stages [23].

In early stages, the clinical and pathological presentation are similar to other inflammatory dermatoses, for example, Atopic eczema. Repeated skin biopsies are usually needed to establish the diagnosis [45]. Treatment of early stage MF includes topical agents (corticosteroid, nitrogen mustards, carmustine, and bexarotene) [6], electron beam therapy, and phototherapy including ultraviolet light, excimer laser, and photodynamic therapy [79].

Many studies involving Western populations showed that NB-UVB is effective for early stage MF [78], but there is lack of studies on NB-UVB in early MF in darker-skinned patients. In this study, we analyzed the efficacy and safety of NB-UVB in patients with skin phototypes III, IV, and V having early stage MF.